William B. Donnellan
About
William B. Donnellan is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, William B. Donnellan has authored 47 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 20 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in William B. Donnellan's work include Acute Myeloid Leukemia Research (27 papers), CAR-T cell therapy research (10 papers) and Chronic Myeloid Leukemia Treatments (9 papers). William B. Donnellan is often cited by papers focused on Acute Myeloid Leukemia Research (27 papers), CAR-T cell therapy research (10 papers) and Chronic Myeloid Leukemia Treatments (9 papers). William B. Donnellan collaborates with scholars based in United States, United Kingdom and Switzerland. William B. Donnellan's co-authors include Rami S. Komrokji, David A. Sallman, Adam S. Asch, Ming Lin, Suman Kambhampati, Chris H. Takimoto, Guido Marcucci, Jens-Peter Volkmer, Paresh Vyas and Joanna Van Elk and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
William B. Donnellan
44 papers receiving 612 citations
Peers
William B. Donnellan
Adam J. Lamble United States
R. Rossi United States
Mayumi Sugita United States
Matthew T. Witkowski United States
Kimihito C. Kawabata Japan
Chelsea J. Gudgeon United States
Line Nederby Denmark
Lemlem Alemu United States
Frauke M. Schnorfeil Germany
Bühring Hj Germany
Citations per year, relative to William B. Donnellan William B. Donnellan (= 1×)
peers
Adam J. Lamble
Countries citing papers authored by William B. Donnellan
Since
Specialization
Citations
This map shows the geographic impact of William B. Donnellan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William B. Donnellan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William B. Donnellan more than expected).
Fields of papers citing papers by William B. Donnellan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William B. Donnellan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William B. Donnellan. The network helps show where William B. Donnellan may publish in the future.
Co-authorship network of co-authors of William B. Donnellan
This figure shows the co-authorship network connecting the top 25 collaborators of William B. Donnellan. A scholar is included among the top collaborators of William B. Donnellan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William B. Donnellan. William B. Donnellan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cortes, Jörge E., Jay Yang, Gail J. Roboz, et al.. (2025). Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood Advances. 9(20). 5293–5305.
2.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274.
3.
Narayan, Rupa, Ana Alfonso Piérola, William B. Donnellan, et al.. (2024). First‐in‐human study of JNJ ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clinical and Translational Science. 17(3). e13742–e13742.
4.
Battiwalla, Minoo, José C. Cruz, William B. Donnellan, et al.. (2024). Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting. PubMed. 6(4). 43–52.
5.
Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.
6.
Donnellan, William B., Jesús G. Berdeja, Michael Byrne, et al.. (2024). Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).. Journal of Clinical Oncology. 42(16_suppl). e13575–e13575.
7.
Patel, Manish R., William B. Donnellan, Michael Byrne, et al.. (2023). Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23(9). 674–686.
8.
Vachhani, Pankit, et al.. (2023). Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting. Cancer Medicine. 12(17). 17914–17923.
9.
Boyiadzis, Michael, Pinkal Desai, William B. Donnellan, et al.. (2022). First‐in‐human study of JNJ ‐63709178, a CD123 /CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clinical and Translational Science. 16(3). 429–435.
10.
McCloskey, James, et al.. (2021). A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592). Transplantation and Cellular Therapy. 27(3). S161–S162.
11.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265.
12.
Matthews, Rachel, David S. Bell, Carlos Bachier, et al.. (2021). The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy. Journal of Oncology Pharmacy Practice. 29(1). 45–51.
13.
Donnellan, William B., et al.. (2020). Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications. Blood. 136(Supplement 1). 11–12.
14.
Patel, Manish R., Guillermo Garcia‐Manero, Ronald Paquette, et al.. (2019). Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. Blood. 134(Supplement_1). 3907–3907.
15.
Cortes, Jörge E., Eunice S. Wang, Justin M. Watts, et al.. (2019). Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. Blood. 134(Supplement_1). 674–674.
16.
Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. Blood. 132(Supplement 1). 466–466.
17.
Sallman, David A., Uma Borate, Elizabeth H. Cull, et al.. (2018). Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type. Blood. 132(Supplement 1). 4066–4066.
18.
Byrne, Michael, William B. Donnellan, Manish R. Patel, et al.. (2017). Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies. Blood. 130. 2585–2585.
19.
Berdeja, Jesús G., Todd M. Bauer, Edward Arrowsmith, et al.. (2017). Phase II study of bendamustine, bortezomib and dexamethasone (BBD ) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. British Journal of Haematology. 177(2). 254–262.
20.
Yang, Jay, Farhad Ravandi, Anjali S. Advani, et al.. (2016). A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). Blood. 128(22). 340–340.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Adam J. Lamble Breakdown of academic impact, for papers by R. Rossi Breakdown of academic impact, for papers by Mayumi Sugita Breakdown of academic impact, for papers by Matthew T. Witkowski Breakdown of academic impact, for papers by Kimihito C. Kawabata Breakdown of academic impact, for papers by Chelsea J. Gudgeon Breakdown of academic impact, for papers by Line Nederby Breakdown of academic impact, for papers by Lemlem Alemu Breakdown of academic impact, for papers by Frauke M. Schnorfeil Breakdown of academic impact, for papers by Bühring Hj